Biogen (NASDAQ:BIIB) Price Target Raised to $185.00 at JPMorgan Chase & Co.

Biogen (NASDAQ:BIIB) had its target price hoisted by JPMorgan Chase & Co. from $175.00 to $185.00 in a research note issued to investors on Thursday morning,MarketScreener reports. JPMorgan Chase & Co. currently has a neutral rating on the biotechnology company’s stock.

BIIB has been the topic of several other research reports. TD Cowen lifted their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Truist Financial decreased their price objective on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a report on Monday, April 13th. Wedbush lifted their price objective on Biogen from $187.00 to $191.00 and gave the stock a “neutral” rating in a report on Wednesday, April 1st. Guggenheim lifted their price objective on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, Wolfe Research set a $231.00 price objective on Biogen in a report on Monday, February 9th. Fourteen investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biogen has an average rating of “Hold” and a consensus price target of $211.31.

Biogen Stock Performance

BIIB opened at $187.88 on Thursday. The firm has a market capitalization of $27.57 billion, a P/E ratio of 21.33, a price-to-earnings-growth ratio of 2.54 and a beta of 0.16. The stock’s 50 day moving average price is $185.37 and its two-hundred day moving average price is $174.82. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. Biogen has a 12-month low of $115.25 and a 12-month high of $202.41.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts forecast that Biogen will post 15.75 earnings per share for the current year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Institutional investors have recently bought and sold shares of the stock. Reflection Asset Management acquired a new stake in Biogen in the 4th quarter valued at $25,000. WPG Advisers LLC boosted its stake in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 117 shares in the last quarter. First Horizon Corp acquired a new stake in Biogen in the 4th quarter valued at $30,000. Root Financial Partners LLC boosted its stake in Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Biogen in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225, citing a “slew of pipeline catalysts” over the next 12–15 months that could materially boost revenue and valuation. Biogen upgraded by UBS on ‘slew of pipeline catalysts’ going into 2027
• Neutral Sentiment: Several analysts issued mixed takes — some raising targets but keeping neutral ratings, which suggests upside is acknowledged but not consensus conviction. This readjusts expectations without flipping broad buy/sell positioning. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB)…
• Neutral Sentiment: JPMorgan raised its price target to $185 but kept a Neutral rating — marginally higher valuation support but still limited upside per their view. MarketScreener: JPMorgan adjusts price target on Biogen to $185
• Neutral Sentiment: Rothschild & Co Redburn raised its target to $180 but kept a Neutral rating — another example of price‑target lift without a buy endorsement. MarketScreener: Rothschild & Co Redburn adjusts Biogen price target to $180
• Neutral Sentiment: Jim Cramer noted he’s “reopening the file” on Biogen after recent coverage and upgrades — a media boost that can support short‑term interest but isn’t an analyst endorsement. Jim Cramer Says “I Got to Reopen the File on Biogen”
• Negative Sentiment: Wolfe Research trimmed its Q1 2026 EPS estimate (from $2.79 to $2.64) even as it nudged FY‑2027 estimates higher — the near‑term cut can pressure the stock ahead of earnings.
• Negative Sentiment: HSBC reiterated a Reduce rating and uses a $150 target — a markedly lower anchor than UBS and others, which can prompt selling by investors who follow conservative sell‑side views. What is HSBC’s Estimate for Biogen Q1 Earnings?
• Neutral Sentiment: Barclays reaffirmed its Hold rating — another stabilizing but non‑bullish stance. Barclays Reaffirms Their Hold Rating on Biogen (BIIB)

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.